Activity of human immunodeficiency virus type 1 protease inhibitors against the initial autocleavage in Gag-Pol polyprotein processing

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 7, 2012, Pages 3620-3628

  Davis, David A ^a   Soule, Erin E ^a,b   Davidoff, Katharine S ^a,c   Daniels, Sarah I ^a,d   Naiman, Nicole E ^a   Yarchoan, Robert ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c GEORGETOWN UNIVERSITY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DARUNAVIR; GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE 1 INHIBITOR; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; INDINAVIR; NELFINAVIR; RITONAVIR; SAQUINAVIR; TIPRANAVIR; UNCLASSIFIED DRUG;

ARTICLE; AUTOCLEAVAGE; CELLULAR PARAMETERS; CONTROLLED STUDY; GENETIC TRANSCRIPTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; PLASMID; PRIORITY JOURNAL; PROTEIN PROCESSING; RNA TRANSLATION; VIRUS NUCLEOCAPSID;

CELL LINE; GENE PRODUCTS, GAG; GENE PRODUCTS, POL; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; SAQUINAVIR; SULFONAMIDES;

EID: 84862551062     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00055-12     Document Type: Article

References (26)

1. Bickel M, et al. 2009. Once-daily treatment with saquinavir mesylate (2000 mg) and ritonavir (100 mg) together with a fixed-dose combination of abacavir/lamivudine (600/300 mg) or tenofovir/emtricitabine (245/200 mg) in HIV-1-infected patients. J. Antimicrob. Chemother. 64: 1260-1264.
2. Bragman K. 1996. Saquinavir: an HIV proteinase inhibitor. Adv. Exp. Med. Biol. 394:305-317.
3. Burlet S, et al. 2005. Prospects for the resistance to HIV protease inhibitors: current drug design approaches and perspectives. Curr. Pharm. Des. 11:3077-3090.
4. Cressey TR, et al. 2005. Low-doses of indinavir boosted with ritonavir in HIV-infected Thai patients: pharmacokinetics, efficacy and tolerability. J. Antimicrob. Chemother. 55:1041-1044.
5. Croom, K. F., and Keam. S. J. 2005. Tipranavir: a ritonavir-boosted protease inhibitor. Drugs 65:1669-1677; discussion, 1678-1679.
6. Daniels SI, et al. 2010. The initial step in human immunodeficiency virus type 1 GagProPol processing can be regulated by reversible oxidation. PLoS One 5:e13595.
7. Davis DA, et al. 2006. Inhibition of HIV-1 replication by a peptide dimerization inhibitor of HIV-1 protease. Antiviral Res. 72:89-99.
8. Ghosh AK, Leshchenko S, Noetzel M. 2004. Stereoselective photochemical 1,3-dioxolane addition to 5-alkoxymethyl-2(5H)-furanone: synthesis of bis-tetrahydrofuranyl ligand for HIV protease inhibitor UIC-94017 (TMC-114). J. Org. Chem. 69:7822-7829.
9. Koh Y, et al. 2007. Potent inhibition of HIV-1 replication by novel nonpeptidyl small molecule inhibitors of protease dimerization. J. Biol. Chem. 282:28709-28720.
10. Kruse G, et al. 2005. The steady-state pharmacokinetics of nelfinavir in combination with tenofovir in HIV-infected patients. Antivir. Ther. 10:349-355.
11. Lefebvre E, Schiffer CA. 2008. Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir. AIDS Rev. 10:131-142.
12. Llibre JM. 2009. First-line boosted protease inhibitor-based regimens in treatment-naive HIV-1-infected patients-making a good thing better. AIDS Rev. 11:215-222.
13. Louis JM, Aniana A, Weber IT, Sayer JM. 2011. Inhibition of autoprocessing of natural variants and multidrug resistant mutant precursors of HIV-1 protease by clinical inhibitors. Proc. Natl. Acad. Sci. U. S. A. 108:9072-9077.
14. Louis JM, Clore GM, Gronenborn AM. 1999. Autoprocessing of HIV-1 protease is tightly coupled to protein folding. Nat. Struct. Biol. 6:868-875.
15. Mitsuya Y, Liu TF, Rhee SY, Fessel WJ, Shafer RW. 2007. Prevalence of darunavir resistance-associated mutations: patterns of occurrence and association with past treatment. J. Infect. Dis. 196:1177-1179.
16. Naggie S, Hicks C. 2010. Protease inhibitor-based antiretroviral therapy in treatment-naive HIV-1-infected patients: the evidence behind the options. J. Antimicrob. Chemother. 65:1094-1099.
17. Pettit SC, Clemente JC, Jeung JA, Dunn BM, Kaplan AH. 2005. Ordered processing of the human immunodeficiency virus type 1 GagPol precursor is influenced by the context of the embedded viral protease. J. Virol. 79:10601-10607.
18. Pettit SC, Everitt LE, Choudhury S, Dunn BM, Kaplan AH. 2004. Initial cleavage of the human immunodeficiency virus type 1 GagPol precursor by its activated protease occurs by an intramolecular mechanism. J. Virol. 78:8477-8485.
19. Pettit SC, Gulnik S, Everitt L, Kaplan AH. 2003. The dimer interfaces of protease and extra-protease domains influence the activation of protease and the specificity of GagPol cleavage. J. Virol. 77:366-374.
20. Ridky T, Leis J. 1995. Development of drug resistance to HIV-1 protease inhibitors. J. Biol. Chem. 270:29621-29623.
21. Roberts NA. 1995. Drug-resistance patterns of saquinavir and other HIV proteinase inhibitors. AIDS 9(Suppl. 2):S27-S32.
22. Schon A, del Mar Ingaramo M, Freire E. 2003. The binding of HIV-1 protease inhibitors to human serum proteins. Biophys. Chem. 105:221-230.
23. Sekar V, et al. 2010. Pharmacokinetics of darunavir/ritonavir and rifabutin coadministered in HIV-negative healthy volunteers. Antimicrob. Agents Chemother. 54:4440-4445.
24. Svicher V, et al. 2005. Novel human immunodeficiency virus type 1 protease mutations potentially involved in resistance to protease inhibitors. Antimicrob. Agents Chemother. 49:2015-2025.
25. Yusa K, Harada S. 2004. Acquisition of multi-PI (protease inhibitor) resistance in HIV-1 in vivo and in vitro. Curr. Pharm. Des. 10:4055-4064.
26. Zhang YM, et al. 1997. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites. J. Virol. 71:6662-6670.